Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
Rongbo Lin, Fuzhou, Fujian, China
Asan Medical Center, Seoul, Korea, Republic of
xiao qing xiao qing Jiang, Shanghai, Shanghai, China
Department of Radiation Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China
Neurosurgery, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
the Second Xiangya Hospital, Changsha, Hunan, China
Jiangsu Provincial Hospital, Nanjing, Jiangsu, China
Junfeng Liu, Shijiazhuang, Hebei, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.